Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
Cortexyme, Inc. announced changes to its leadership team, including appointing Christopher Lowe as interim chief executive officer.
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
Together, these two companies are combining their strengths to find treatment options for rare neuromuscular diseases.
This week, two biotechnology firms announced new leadership, David Nassif, J.D., and Christophe Bourdon.
The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.
One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.
The union has one primary goal – speed up discovery and development to get effective drugs to patients sooner.
What makes a candidate attractive? For Deschoolmeester, three critical elements stand out: pragmatism, creativity and collaboration.
TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.